JOHN KIRKWOOD to Immunotherapy, Adoptive
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Immunotherapy, Adoptive.
Connection Strength
0.390
-
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Nov 20; 43(33):3565-3572.
Score: 0.142
-
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol. 1998 Dec; 114(3):347-54.
Score: 0.091
-
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
Score: 0.087
-
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007 Jan; 30(1):75-82.
Score: 0.040
-
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 12; 10(12).
Score: 0.030